| For immediate release | 14 February 2017 |
("Alliance" or the "Company")
PDMR shareholding
Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, announces that Peter Butterfield, a director of the Company and its Deputy CEO has today exercised an option granted under an employee share scheme over 90,222 ordinary shares of 1p each in the Company at 33.25p per share, and immediately sold 61,846 of these shares on the London Stock Exchange at a price of 48.75p per share to fund the subscription price and associated dealing costs.
Following these linked transactions, Mr Butterfield has a beneficial interest in 28,376 shares in the Company and holds options over a further 4,349,803 shares granted under the Company's employee share schemes.
For further information:
| Alliance Pharma plc | + 44 (0) 1249 466966 |
| John Dawson, Chief Executive Andrew Franklin, Chief Financial Officer | |
| Rob Bellhouse, Company Secretary | |
| www.alliancepharma.co.uk | |
| Buchanan | + 44 (0) 20 7466 5000 |
| Mark Court / Sophie Cowles / Jane Glover | |
| | |
| Numis Securities Limited | + 44 (0) 20 7260 1000 |
| Nominated Adviser: Michael Meade / Freddie Barnfield | |
| Corporate Broking: James Black / Toby Adcock | |
Notes to editors:
About Alliance Pharma
Alliance, founded in 1998, is an international speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has sales in more than 100 countries worldwide via direct sales, joint ventures and a network of distributors. Alliance has a strong track record of acquiring the rights to established niche products and it currently owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. The Company continues to explore opportunities to expand its product portfolio.
Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.
ANNEX
Template for notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
| 1
| Details of the person discharging managerial responsibilities / person closely associated
| |||||
| a)
| Name
| Peter Butterfield | ||||
| 2
| Reason for the notification
| |||||
| a)
| Position/status
| Deputy Chief Executive Officer | ||||
| b)
| Initial notification /Amendment
| Initial | ||||
| 3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| |||||
| a)
| Name
| Alliance Pharma plc | ||||
| b)
| LEI
| n/a | ||||
| 4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| |||||
| a)
| Description of the financial instrument, type of instrument
Identification code
| 1p ordinary shares
ISIN: GB0031030819
| ||||
| b)
| Nature of the transaction
| 1. Exercise of options 2. Sale | ||||
| c)
| Price(s) and volume(s)
|
| ||||
| d)
| Aggregated information
- Aggregated volume
- Price
| Exercise of 90,222 options at an exercise price of 33.25p per share
Sale of 61,846 shares at a price of 48.75p per share | ||||
| e)
| Date of the transaction
| 14 February 2017 | ||||
| f)
| Place of the transaction
| London Stock Exchange, AIM | ||||